Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Science Translational Medicine|March 16, 2021
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individualsTatjana Bilich, Annika Nelde, Jonas S Heitmann, et al.
Frontiers in Oncology|April 12, 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusionChristopher Hackenbruch, Jens Bauer, Jonas S Heitmann, et al.
Clinical & Translational Immunology|September 6, 2021
Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohortsDonjete Simnica, Christoph Schultheiß, Malte Mohme, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy developmentSteffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, et al.
Cancer Discovery|May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerTatjana Bilich, Malte Roerden, Yacine Maringer, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.
Nature|November 23, 2021
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Blood Cancer Discovery|October 17, 2023
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor CellsAnnika Nelde, Heiko Schuster, Jonas S Heitmann, et al.
Pageof 3